97 related articles for article (PubMed ID: 33619913)
21. Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response.
Pabla S; Seager RJ; Van Roey E; Gao S; Hoefer C; Nesline MK; DePietro P; Burgher B; Andreas J; Giamo V; Wang Y; Lenzo FL; Schoenborn M; Zhang S; Klein R; Glenn ST; Conroy JM
Biomark Res; 2021 Jul; 9(1):56. PubMed ID: 34233760
[TBL] [Abstract][Full Text] [Related]
22. Identification and validation of the association of Janus kinase 2 mutations with the response to immune checkpoint inhibitor therapy.
Chen P; Long J; Zhang J; Xie F; Wu W; Tian Z; Zhang S; Yu K
Inflamm Res; 2024 Feb; 73(2):263-276. PubMed ID: 38200372
[TBL] [Abstract][Full Text] [Related]
23. Successful Treatment of Metastatic Gallbladder Carcinoma with a High Tumor Mutational Burden Using Pembrolizumab.
Uehara S; Naganuma A; Furuichi N; Furusawa A; Kaburagi T; Naruse H; Tomaru S; Sano N; Suzuki Y; Masuda T; Hoshino T; Yasuoka H; Tanaka Y; Saito S; Hatanaka T; Kakizaki S
Intern Med; 2023 Nov; 62(21):3151-3156. PubMed ID: 36927965
[TBL] [Abstract][Full Text] [Related]
24. Impact of age on the toxicity of immune checkpoint inhibition.
Samani A; Zhang S; Spiers L; Suwaidan AA; Merrick S; Tippu Z; Payne M; Faust G; Papa S; Fields P; Van Hemelrijck M; Josephs DH
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33033183
[TBL] [Abstract][Full Text] [Related]
25. Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry.
Mostaghim A; Minkove S; Aguilar-Company J; Ruiz-Camps I; Eremiev-Eremiev S; Dettorre GM; Fox L; Tondini C; Brunet J; Carmona-García M; Lambertini M; Bower M; Newsom-Davis T; Sharkey R; Pria AD; Rossi M; Plaja A; Salazar R; Sureda A; Prat A; Michalarea V; Van Hemelrijck M; Sita-Lumsden A; Bertuzzi A; Rimassa L; Rossi S; Rizzo G; Pedrazzoli P; Lee AJ; Murphy C; Belessiotis K; Diamantis N; Mukherjee U; Pommeret F; Stoclin A; Martinez-Vila C; Bruna R; Gaidano G; D'Avanzo F; Gennari A; Athale J; Eichacker P; Pinato DJ; Torabi-Parizi P; Cortellini A;
Int J Infect Dis; 2024 Feb; 139():13-20. PubMed ID: 38029831
[TBL] [Abstract][Full Text] [Related]
26. Comment on "Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta‑Analysis".
Ma J; Han W
Mol Diagn Ther; 2024 May; 28(3):345-346. PubMed ID: 38600343
[No Abstract] [Full Text] [Related]
27. Real-world treatment outcomes of immune checkpoint inhibitors used off-label in oncology: A comprehensive cancer institution experience.
Fontanals S; Esteve A; González A; Ibáñez C; Mesía R; Clopés A
Pharmacol Res Perspect; 2024 Feb; 12(1):e1167. PubMed ID: 38193611
[TBL] [Abstract][Full Text] [Related]
28. From standard therapies to monoclonal antibodies and immune checkpoint inhibitors - an update for reconstructive surgeons on common oncological cases.
Knoedler L; Huelsboemer L; Hollmann K; Alfertshofer M; Herfeld K; Hosseini H; Boroumand S; Stoegner VA; Safi AF; Perl M; Knoedler S; Pomahac B; Kauke-Navarro M
Front Immunol; 2024; 15():1276306. PubMed ID: 38715609
[TBL] [Abstract][Full Text] [Related]
29. A Large-Scale Meta-Analysis Reveals Positive Feedback between Macrophages and T Cells That Sensitizes Tumors to Immunotherapy.
Yang J; Liu Q; Shyr Y
Cancer Res; 2024 Feb; 84(4):626-638. PubMed ID: 38117502
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy Use in Patients With Lung Cancer and Comorbidities.
von Itzstein MS; Gonugunta AS; Mayo HG; Minna JD; Gerber DE
Cancer J; 2020; 26(6):525-536. PubMed ID: 33298724
[TBL] [Abstract][Full Text] [Related]
31. Chemokine expression predicts T cell-inflammation and improved survival with checkpoint inhibition across solid cancers.
Romero JM; Titmuss E; Wang Y; Vafiadis J; Pacis A; Jang GH; Zhang A; Golesworthy B; Lenko T; Williamson LM; Grünwald B; O'Kane GM; Jones SJM; Marra MA; Wilson JM; Gallinger S; Laskin J; Zogopoulos G
NPJ Precis Oncol; 2023 Aug; 7(1):73. PubMed ID: 37558751
[TBL] [Abstract][Full Text] [Related]
32. A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma.
Wilhite AM; Wu S; Xiu J; Gibney GT; Phung T; In GK; Herzog TJ; Khabele D; Erickson BK; Brown J; Rocconi RP; Pierce JY; Scalici JM; Jones NL
Gynecol Oncol; 2024 Jun; 188():13-21. PubMed ID: 38861917
[TBL] [Abstract][Full Text] [Related]
33. Two types of fulminant type 1 diabetes mellitus: Immune checkpoint inhibitor-related and conventional.
Imagawa A
J Diabetes Investig; 2021 Jun; 12(6):917-919. PubMed ID: 33098749
[TBL] [Abstract][Full Text] [Related]
34. Persistent Tumor Mutational Burden (pTMB) May Predict Response to Immune Checkpoint Inhibitors.
Smith KER; Markovic SN
Clin Chem; 2024 Jan; 70(1):25-26. PubMed ID: 38175581
[No Abstract] [Full Text] [Related]
35. Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes.
Wong MK; Kaufman HL; Daniels GA; McDermott DF; Aung S; Lowder JN; Morse MA
J Immunother Cancer; 2014; 2():20. PubMed ID: 25031835
[TBL] [Abstract][Full Text] [Related]
36. Author Correction: Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma.
Patterson A; Auslander N
Nat Commun; 2023 Sep; 14(1):5865. PubMed ID: 37735162
[No Abstract] [Full Text] [Related]
37. Predictors of response and resistance to checkpoint inhibitors in solid tumors.
Rao SV; Moran AE; Graff JN
Ann Transl Med; 2017 Dec; 5(23):468. PubMed ID: 29285501
[No Abstract] [Full Text] [Related]
38. A cohesive look at leukemogenesis: The cohesin complex and other driving mutations in AML.
Heimbruch KE; Meyer AE; Agrawal P; Viny AD; Rao S
Neoplasia; 2021 Mar; 23(3):337-347. PubMed ID: 33621854
[TBL] [Abstract][Full Text] [Related]
39. Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms.
Van Egeren D; Escabi J; Nguyen M; Liu S; Reilly CR; Patel S; Kamaz B; Kalyva M; DeAngelo DJ; Galinsky I; Wadleigh M; Winer ES; Luskin MR; Stone RM; Garcia JS; Hobbs GS; Camargo FD; Michor F; Mullally A; Cortes-Ciriano I; Hormoz S
Cell Stem Cell; 2021 Mar; 28(3):514-523.e9. PubMed ID: 33621486
[TBL] [Abstract][Full Text] [Related]
40. Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia.
Wang D; Wang N; Li X; Chen X; Shen B; Zhu D; Zhu L; Xu Y; Yu Y; Shu Y
Gastric Cancer; 2021 Jul; 24(4):823-834. PubMed ID: 33687617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
